The Hemostats and Sealants Market continues to grow at a steady clip. SmartTRAK projects this market will reach more than $3.5B by 2022E with a five-year CAGR of ~5%.
It’s good news for many, but do you know the real story behind those numbers?
SmartTRAK identifies what’s driving growth in the global Hemostats and Sealants market. In this Market Outlook article, Doug Devens, SmartTRAK's Senior Analyst, Biosurgery, does a deep dive, discussing what’s fueling this growth and reviews the top market trends you need to know for the year ahead.
Download Market Outlook: Top Trends to Watch in Hemostats and Sealants
Overall market growth worldwide will be based on continued rapid growth in fibrin sealants and the new class of starch-based absorbable hemostats. New products in China and the US, as well as continued use for new indications, will sustain growth in the fibrin sealant segment. PerClot’s arrival in 2019 and the associated launch campaign from Cryolife should drive the transition to this class of starch-based hemostats even faster. While Arista may see some losses from PerClot’s arrival, we predict the segment overall will grow even more rapidly. Finally, biologic sealants should resume their contribution to the growth of the segment, with the relaunch of Progel by BD and launches in new countries by Cryolife and Baxter...
Doug Devens, SmartTRAK's Senior Analyst, Biosurgery, took an exclusive deep dive into the market, which includes thrombin hemostats, absorbable hemostats, fibrin sealants, synthetic sealants and biologic sealants. SmartTRAK’s Market Outlook for Hemostats and Sealants explores what’s fueling this growth and reviews the top market trends you need to know for the year ahead.